Novel HER2 Drug Shrinks Lung Cancer Tumors in Early Trial

(MedPage Today) — BERLIN — An investigational oral drug currently under review with the FDA showed durable antitumor activity in patients with HER2-mutant advanced non-small cell lung cancer (NSCLC), findings from an international phase I/II…

Source link : https://www.medpagetoday.com/meetingcoverage/esmo/118084

Author :

Publish date : 2025-10-22 17:31:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Novel HER2 Drug Shrinks Lung Cancer Tumors in Early Trial

Could This Be the First Disease-Modifying Drug in Bronchiectasis?

An excellent guide to the labyrinthine world of COP summits

Related Posts

Trump Announces Lower Drug Price Deals With 9 Pharmaceutical Companies

Polatuzumab-Based Combination Continues to Impress in Real-World DLBCL Analyses

Sniffing Out the Optimal Radiation Dose for Head and Neck Cancer

Fellow Nurses: Did You (or Will You) Go to Your Staff Christmas Party?

Cheddar Cheese Recalled; Nick Reiner’s Medication Change; How Safe Is U.S. Food?

Novel Treatment Combo Ups Survival in Multiple Myeloma

Trump Announces Lower Drug Price Deals With 9 Pharmaceutical Companies

Polatuzumab-Based Combination Continues to Impress in Real-World DLBCL Analyses

Sniffing Out the Optimal Radiation Dose for Head and Neck Cancer

Fellow Nurses: Did You (or Will You) Go to Your Staff Christmas Party?

Cheddar Cheese Recalled; Nick Reiner’s Medication Change; How Safe Is U.S. Food?

Novel Treatment Combo Ups Survival in Multiple Myeloma

Hallucinogen Emergency Care May Predict Mania, BD Risk

NICE Endorses Chemo-Free First-Line Option for EGFR NSCLC

Categories

Archives